Article
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
Molecular medicine reports - 1 Apr 2015
Zhao Bao-Xia, Wang Jing, Song Bo, Wei Hong, Lv Wei-Peng, Tian Li-Min, Li Mei, Lv Shen
Abstract excerpt
Non‑small cell lung cancer (NSCLC) cells harboring mutations in the epidermal growth factor receptor (EGFR) gene initially respond well to EGFR tyrosine kinase inhibitors (TKI), including gefitinib. However the tumor cells will invariably develop acquired resistance to the drug. The EGFR T790M mutation is generally considered to be the molecular genetic basis of acquired TKI resistance. The present study aimed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.